Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Acute Leukemias - Republican Scientific Medical Library
Create successful ePaper yourself
Turn your PDF publications into a flip-book with our unique Google optimized e-Paper software.
144 Chapter 10 · Recent Clinical Trials in <strong>Acute</strong> Lymphoblastic Leukemia by the Cancer and Leukemia Group B<br />
References<br />
1. Larson RA, Dodge RK, Burns CP, Lee EJ, Stone RM, Schulman P,<br />
Duggan D, Davey FR, Sobol RE, Frankel SR, et al. (1995) A five-drug<br />
remission induction regimen with intensive consolidation for<br />
adults with acute lymphoblastic leukemia: Cancer and Leukemia<br />
Group B study 8811. Blood 85:2025–2037<br />
2. Gottlieb AJ, Weinberg V, Ellison RR, Henderson ES, Terebelo H, Rafla<br />
S, Cuttner J, Silver RT, Carey RW, Levy RN, et al. (1984) Efficacy of<br />
daunorubicin in the therapy of adult acute lymphocytic leukemia:<br />
A prospective randomized trial by Cancer and Leukemia Group B.<br />
Blood 64:267–274<br />
3. Ellison RR, Mick R, Cuttner J, Schiffer CA, Silver RT, Henderson ES,<br />
Woliver T, Royston I, Davey FR, Glicksman AS, et al. (1991) The effects<br />
of postinduction intensification treatment with cytarabine<br />
and daunorubicin in acute lymphocytic leukemia: A prospective<br />
randomized clinical trial by Cancer and Leukemia Group B. J Clin<br />
Oncol 9:2002–2015<br />
4. Hoelzer D, Thiel E, Löffler H, Büchner T, Ganser A, Heil G. Koch P,<br />
Freund M, Diedrich H, Rühl H, et al. (1988) Prognostic factors in a<br />
multicenter study for treatment of acute lymphoblastic leukemia<br />
in adults. Blood 71:123–131<br />
5. Sobol RE, Mick R, Royston I, Davey FR, Ellison RR, Newman R, Cuttner<br />
J, Griffin JD, Collins H, Nelson DA, et al. (1987) Clinical importance<br />
of myeloid antigen expression in adult acute lymphoblastic<br />
leukemia. N Engl J Med 316:1111–1117<br />
6. Larson RA, Dodge RK, Linker CA, Stone RM, Powell BL, Lee EJ,<br />
Schulman P, Davey FR, Frankel SR, Bloomfield CD, et al. (1998)<br />
A randomized controlled trial of filgrastim during remission induction<br />
and consolidation chemotherapy for adults with acute<br />
lymphoblastic leukemia: CALGB study 9111. Blood 92:1556–<br />
1564<br />
7. Grossbard ML, Freedman AS, Ritz J, Coral F, Goldmacher VS, Eliseo<br />
L, Spector N, Dear K, Lambert JM, Blättler WA, T, et al. (1992) Serotherapy<br />
of B-cell neoplasms with anti-B4-blocked ricin: A phase I<br />
trial of daily bolus infusion. Blood 79:576–585<br />
8. Szatrowski TP, Dodge RK, Reynolds C, Westbrook CA, Frankel SR,<br />
Sklar J, Stewart C, Hurd D, Kolitz JE, Velez-Garcia E, et al. (2003)<br />
Lineage specific treatment of adult patients with acute lymphoblastic<br />
leukemia in first remission with anti-B4-blocked ricin or<br />
high-dose cytarabine: Cancer and Leukemia Group B study<br />
9311. Cancer 97:1471–1480<br />
9. Larson RA, Fretzin MH, Dodge RK, Schiffer CA (1998) Hypersensitivity<br />
reactions to L-asparaginase do not impact on the remission<br />
duration of adults with acute lymphoblastic leukemia. Leukemia<br />
12:660–665<br />
10. Asselin BL, Whitin JC, Coppola DJ, Rupp IP, Sallan SE, Cohen HJ<br />
(1993) Comparative pharmacokinetic studies of three asparaginase<br />
preparations. J Clin Onc 11:1780–1786<br />
11. Kurtzberg J, Asselin B, Pollack B, Bernstein M, Buchanan G (1993)<br />
The Pediatric Oncology Group: PEG-L-Asparaginase (PEGasp) vs<br />
native E coli asparaginase (asp) for reinduction of relapsed acute<br />
lymphoblastic leukemia (ALL): POG #8866 Phase II trial. Proc Am<br />
Soc Clin Oncol 12:325<br />
12. Frankel SR, Kurtzberg J, DeOleivera D, Dodge R, Peterson B, Powell<br />
BL, Larson RA, Schiffer CA (1996) Toxicity and pharmacokinetics of<br />
peg-asparaginase (peg-asp) in newly diagnosed adult acute lymphoblastic<br />
leukemia (ALL): CALGB 9511. Blood 88(Suppl 1):669a<br />
13. Frankel SR, Kurtzberg J, DeOliveria D, Dodge R, Peterson B, Powell<br />
BL, Kolitz J, Larson RA, Schiffer CA (1997) Toxicity and pharmacokinetics<br />
of PEG-asparaginase (PEG-asn) in newly diagnosed adult<br />
acute lymphoblastic leukemia (ALL): CALGB 9511. Blood 90(Suppl<br />
1):334a<br />
14. Lee EJ, Petroni GR, Schiffer CA, Freter CE, Johnson JL, Barcos M,<br />
Frizzera G, Bloomfield CD, Peterson BA (2001) Brief-duration<br />
high-intensity chemotherapy for patients with small noncleaved-cell<br />
lymphoma or FAB L3 acute lymphocytic leukemia: Results<br />
of Cancer and Leukemia Group B study 9251. J Clin Oncol<br />
19(20):4014–4022<br />
15. Rizzieri DA Johnson JL, Niedzwiecki D, Lee EJ, Vardiman JW, Powell<br />
BL, Barcos M, Bloomfield CD, Schiffer CA, Peterson BA, et al. (2004)<br />
Intensive chemotherapy with and without cranial radiation for<br />
Burkitt leukemia and lymphoma: Final results of Cancer and Leukemia<br />
Group B study 9251. Cancer 100:1438–1448<br />
16. Hoelzer D, Ludwig WD, Thiel E, Gabmann W, Loffler H, Fonatsch C,<br />
et al. (1996) Improved outcome in adult B-cell acute lymphoblastic<br />
leukemia. Blood 88:495–508<br />
17. Stock W, Dodge RK, Vardiman JW, Bloomfield CD, Caligiuri MA,<br />
Frankel S, Stone RM, Larson RA (2001) Treatment of adult acute<br />
lymphoblastic leukemia: Phase II trial of dose intensification of<br />
daunorubicin and cytarabine followed by high-dose methotrexate<br />
and intrathecal methotrexate in place of cranial irradiation<br />
(CALGB 19802). Blood 98(Suppl 1):590a (#2472)<br />
18. Stock W, Yu D, Johnson J, Bloomfield CD, Stone RM, Kolitz JE, Wetzler<br />
M, Powell B, Vardiman JW, Larson RA (2003) Intensified daunorubicin<br />
during induction and postremission therapy of adult acute<br />
lymphoblastic leukemia (ALL): Results of CALGB 19802. Blood<br />
102:379a (#1375)<br />
19. Wetzler M, Dodge RK, Mrozek K, Carroll AJ, Tantravahi RR, Block<br />
AMW, Pettenati MJ, Le Beau MM, Frankel SR, Stewart CC, et al.<br />
(1999) Prospective karyotype analysis in adult acute lymphoblastic<br />
leukemia: The Cancer and Leukemia Group B Experience. Blood<br />
93:3983–3993<br />
20. Gandhi V, Plunkett W, Rodriquez CO Jr, Nowak BJ, Du M, Ayres M,<br />
Kisor DF, Mitchell BS, Kurtzberg J, Keating MJ (1998) Compound<br />
GW506U78 in refractory hematological malignancies: Relationship<br />
between cellular pharmacokinetics and clinical response. J<br />
Clin Oncol 16:3607–3615<br />
21. De Angelo DJ, Yu D, Johnson JL, Coutre SE, Stone RM, Stopeck AT,<br />
Gockermann JP, Mitchell BS, Appelbaum FR, Larson RA (2007) A<br />
phase II study of 2-amino-9-D-arabinosyl-6-methoxy-9H-purine<br />
(506U78) in patients with relapsed or refractory T-lineage acute<br />
lymphoblastic leukemia (ALL) or lymphoblastic lymphoma<br />
(LBL): CALGB Study 19801. Blood 109:5136–5142